Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Twenty-year follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study
Author Affiliations & Notes
  • Alexandra Pietraszkiewicz
    National Eye Institute, Bethesda, Maryland, United States
  • Elvira Agron
    National Eye Institute, Bethesda, Maryland, United States
  • Chandana Papudesu
    National Eye Institute, Bethesda, Maryland, United States
  • Tiarnan D L Keenan
    National Eye Institute, Bethesda, Maryland, United States
  • Wai T. Wong
    National Eye Institute, Bethesda, Maryland, United States
  • Emily Chew
    National Eye Institute, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Alexandra Pietraszkiewicz, None; Elvira Agron, None; Chandana Papudesu, None; Tiarnan Keenan, None; Wai Wong, None; Emily Chew, None
  • Footnotes
    Support  AREDS: Supported by the intramural program funds and contracts AREDS (Contract NOI-EY-0-2127) from the National Eye Institute/ National Institutes of Health, Department of Health and Human Services, Bethesda, MD. AREDS2: Supported by the intramural program funds and contracts from the National Eye Institute/ National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland (contract HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007). Funds were generously contributed to these contracts by the following NIH institutes: Office of Dietary Supplements, National Center for Complementary and Alternative Medicine; National Institute on Aging; National Heart, Lung, and Blood Institute, and National Institute of Neurological Disorders and Stroke.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4178. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexandra Pietraszkiewicz, Elvira Agron, Chandana Papudesu, Tiarnan D L Keenan, Wai T. Wong, Emily Chew; Twenty-year follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4178.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Data on long-term outcomes and risk factors for progression of age-related macular degeneration (AMD) beyond 15 years are limited. We performed a retrospective analysis of a subset of participants enrolled in the prospective cohort study, the Age-Related Eye Disease Study (AREDS), who had 20 years of follow-up to evaluate risk factors associated with progression to intermediate and late AMD.

Methods : We observed AREDS participants through their subsequent participation in either AREDS2 or the NEI extended follow-up protocol after completion of a randomized clinical trial of antioxidant vitamins and minerals. Participants were 55 to 80 years old with no AMD or AMD of varying severity. Annual stereoscopic fundus photographs were graded centrally and evaluated for large drusen, geographic atrophy (GA), and choroidal neovascularization (CNV). Analyses were conducted on 171 surviving participants followed annually. The unit of analysis was the eye, with n=319 for late AMD, n=193 for large drusen, and n=279 for genetics. Kaplan-Meier analyses and multivariable proportional hazard regressions were performed. Covariates included age, sex, race, education level, smoking status, baseline AREDS AMD severity score, 52-single nucleotide polymorphism (SNP) Genetic Risk Score (GRS), and four SNPs.

Results : Overall, 40% of eyes progressed to late AMD with a mean time to event of 18.6 years (SEM 0.4), and 51% of eyes developed large drusen with a mean time to event of 12.2 years (SEM 0.5). Time to late AMD and large drusen decreased with increasing baseline severity. For progression to late AMD, risk factors included older age (HR 1.1, CI 1.0—1.2, P=.001), higher baseline severity (scale 4-6 vs. 1-3: HR 4.7, CI 2.8—7.8; scale 7-8 vs. 1-3: HR 13.3, CI 6.9—25.6, P<.0001), higher GRS (GRS 1 vs. 0: HR 2.6, CI 1.1—6.2, P=.03; GRS 2 vs. 0: HR 4.9, CI 2.1—11.6, P=.0003), CFH rs1061170 (2 vs. 0 alleles: HR 2.3, CI 1.1—4.6, P=.027), and ARMS2 rs10490924 (2 vs. 0 alleles: HR 2.4, CI 1.4—4.1, P=.002). Baseline AMD score ≥ 1 was the only risk factor for progression to large drusen (HR 3.8, CI 2.3—6.4, P<.0001).

Conclusions : The risk factors for AMD progression are similar to those described in previous studies and include older age, higher baseline AMD severity score, higher GRS, CFH and ARMS2. This study provides novel insight into long-term progression to large drusen, which does not share the same risk factors as late AMD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×